
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc reported a significant 81% year-over-year increase in Q4 FY25 revenues, largely attributed to enhanced Nociscan report volumes, particularly in the UK. The company is actively expanding its market presence, evidenced by the 31% year-over-year revenue growth in Q3 FY25 and a substantial 114% increase in Nociscan scan volume in Q4, indicating strong commercial momentum. Furthermore, the strategic enrollment in the CLARITY trial and favorable coverage decisions by private UK insurers underscore potential for sustained growth and adoption of Aclarion's innovative healthcare technologies.
Bears say
Aclarion Inc faces a challenging financial landscape reflected in its projected fiscal year 2025 earnings per share (EPS) estimate, which has been lowered from a previous estimate, indicating increasing operating expenses that may hinder profitability. The company is also grappling with multiple risks including slower adoption of its Nociscan product among surgeons, potential balance sheet and liquidity issues, and the ability to secure necessary regulatory approvals and reimbursement for its services. Furthermore, the heightened operating expenses relative to expectations, combined with market uncertainties related to competition and consumer attitudes, contribute to a negative outlook for Aclarion's stock performance.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares